Poxel is focsed on targeting cellular energy for the treatment of type 2 diabetes, saying: "We believe that it represents the root of the disease." Imeglimin, the company's lead program, targets mitochondrial dysfunction and PXL770 targets adenosine monophosphate-activated protein kinase (AMPK).